Journal of Internal Medicine Concepts & Practice >

2023 , Vol. 18 >Issue 01: 18 - 21

DOI: https://doi.org/10.16138/j.1673-6087.2023.01.006

Specification and implementation plan

Guidelines for clinical management of novel coronavirus infection in pituitary disease

Expand

Received date: 2023-01-15

  Online published: 2023-02-13

Fold

Cite this article

Chinese Society of Endocrinology . Guidelines for clinical management of novel coronavirus infection in pituitary disease[J]. Journal of Internal Medicine Concepts & Practice, 2023 , 18(01) : 18 -21 . DOI: 10.16138/j.1673-6087.2023.01.006

References

[1] Yuen KCJ, Blevins LS Jr, Findling JW. Important ma-nagement considerations in patients with pituitary disorders during the time of the Covid-19 pandemic[J]. Endocr Pract, 2020, 26(8): 915-922.
[2] Fleseriu M, Dekkers OM, Karavitaki N. Endocrinology in the time of COVID-19: management of pituitary tumours[J]. Eur J Endocrinol, 2020, 183(1): G17-G23.
[3] Fleseriu M, Buchfelder M, Cetas JS, et al. Pituitary Society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective[J]. Pituitary, 2020, 23(4): 327-337.
[4] Christ-Crain M, Hoorn EJ, Sherlock M, et al. Endocrinology in the time of COVID-19: management of diabetes insipidus and hyponatraemia[J]. Eur J Endocrinol, 2020, 183(1): G9-G15.
[5] Christ-Crain M, Hoorn EJ, Sherlock M, et al. Endocrinology in the time of COVID-19-2021 updates: the management of diabetes insipidus and hyponatraemia[J]. Eur J Endocrinol, 2021, 185(4): G35-G42.
[6] 中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 751-760.
[7] 中国垂体腺瘤协作组. 中国肢端肥大症诊治共识(2021版)[J]. 中华医学杂志, 2021, 101(27): 2115-2126.
[8] 中国垂体腺瘤协作组. 中国库欣病诊治专家共识(2015)[J]. 中华医学杂志, 2016, 96(11): 835-840.
[9] Isidori AM, Arnaldi G, Boscaro M, et al. COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency[J]. J Endocrinol Invest, 2020, 43(8): 1141-1147.
[10] Arlt W, Baldeweg SE, Pearce SHS, et al. Endocrinology in the time of COVID-19: management of adrenal insufficiency[J]. Eur J Endocrinol, 2020, 183(1): G25-G32.
[11] Pal R, Joshi A, Bhadada SK, et al. Endocrine follow-up during post-acute COVID-19: practical recommendations based on available clinical evidence[J]. Endocr Pract, 2022, 28(4): 425-432.
[12] 中华医学会内分泌学分会肥胖学组. 肾上腺皮质功能减退症患者围手术期糖皮质激素管理专家共识[J]. 中华内分泌代谢杂志, 2022, 38(1): 1-6.
[13] Clarke SA, Abbara A, Dhillo WS. Impact of COVID-19 on the endocrine system: a mini-review[J]. Endocrinology, 2022, 163(1):bqab203.
[14] Tan T, Khoo B, Mills EG, et al. Association between high serum total cortisol concentrations and mortality from COVID-19[J]. Lancet Diabetes Endocrinol, 2020, 8(8): 659-660.
[15] Tan T, Khoo B, Mills EG, et al. Cortisol concentrations and mortality from COVID-19 - authors’ reply[J]. Lancet Diabetes Endocrinol, 2020, 8(10):809-810.
[16] Pivonello R, Ferrigno R, Isidori AM, et al. COVID-19 and Cushing’s syndrome: recommendations for a special population with endogenous glucocorticoid excess[J]. Lancet Diabetes Endocrinol, 2020, 8(8): 654-656.
[17] Newell-Price J, Nieman LK, Reincke M, et al. Endocrinology in the time of COVID-19: management of Cushing’s syndrome[J]. Eur J Endocrinol, 2020, 183(1): G1-G7.
[18] 王卫庆, 单忠艳, 王广, 等. 新型冠状病毒肺炎疫情期间糖尿病基层管理专家建议[J]. 中华内分泌代谢杂志, 2020, 36(3): 185-190.
[19] 中国医师协会内分泌代谢科医师分会, 中国住院患者血糖管理专家组. 中国住院患者血糖管理专家共识[J]. 中华内分泌代谢杂志, 2017, 33(1): 1-10.
[20] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志, 2021, 37(4): 311-398.
Options
Outlines

/

〈 〉